We are studying whether Luspatercept can improve anemia in patients with lower-risk myelodysplastic syndromes who do not require blood transfusions. The trial will also assess its impact on quality of life and safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Myelodysplastic Syndromes (MDS) are a group of disorders caused by poorly formed or dysfunctional blood cells, often leading to symptoms like anemia, fatigue, and a higher risk of infections. Patients may require treatments to manage their anemia and improve blood cell production.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.